Have a personal or library account? Click to login
Complex Multidisciplinary Follow-Up Of Children With Neurofibromatosis Type 1 Cover

Complex Multidisciplinary Follow-Up Of Children With Neurofibromatosis Type 1

European Pharmaceutical Journal
Volume 61 (2014): Issue 1 (August 2014)
By: A. Bolčeková,  A. Hlavatá,  A. Zat'ková,  M. Némethová,  M. Holobradá,  P. Sýkora,  A. Gerinec,  K. Husáková,  D. Ilenčíková and  L Kovács  
Open Access
|Aug 2014

References

  1. [1] Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, Mc-Cluggage C Plon SE. Outcomes of systematic screening for optic pathway tumors in children with neurofibroma-tosis type 1. Am J Med Genet. 2004;127A:224-229.10.1002/ajmg.a.2065015150770
    Search in Google Scholar
  2. [2] Bolcekova A, Nemethova M, Zatkova A Hlinkova K, Pozgayova S, Hlavata A, Kadasi L, Durovcikova D, Gerinec A, Husakova K, Pavlovicova Z, Holobrada M, Kovacs L, Ilencikova D. Clustering of mutations in the 5’ tertile of the NF1 gene in Slovakia patients with optic pathway glioma, Neoplasma. 2013;60 (6):655-65.10.4149/neo_2013_08423906300
    Search in Google Scholar
  3. [3] Brown EW, Riccardi VM, Mawad M, Handel S, Goldman A, Bryan RN. MR imaging of optic pathways in patients with Neurofibromatosis. Am J Neuroradiol. 1987;8:1031-1036.
    Search in Google Scholar
  4. [4] Brzowski AE, Bazan C, Mumma JV, Ryan SG. Spontaneous regression of optic glioma in a patient with neurofibro-matosis, Neurology 1992;42:679-681.10.1212/WNL.42.3.6791549238
    Search in Google Scholar
  5. [5] Czyzyk E, Jozwiak S, Roskowski M, Schwartz RA. Optic pathway gliomas in children with and without neurof-bromatosis type1. J Child Neurol. 2003;18:471-478.10.1177/0883073803018007040112940652
    Search in Google Scholar
  6. [6] De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, Mautner V, Frahm S, Sciot R, Legius E. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003;72:1288–1292.10.1086/374821118028112660952
    Search in Google Scholar
  7. [7] DeBella K, Szudek J, Friedman JM. Use of the National Institutes of Health criteria for diagnosis of neurofibroma-tosis 1 in children. Pediatrics. 2000;105:608-14.10.1542/peds.105.3.60810699117
    Search in Google Scholar
  8. [8] DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) Neurofibromatosis. Cell. 1999;69, 265-273.
    Search in Google Scholar
  9. [9] Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in Neurofibromatosis 1. J Med Genet 2002;39:311-410.1136/jmg.39.5.311173512212011145
    Search in Google Scholar
  10. [10] Feldmann R, Denecke J, Grenzebach M, Schuierer G, We-glage. Neurofibromatosis type 1: Motor and cognitive function and T2-weighted MRI hyperintensities. J Neurology. 2003; Dec 23;61(12):1725-8.10.1212/01.WNL.0000098881.95854.5F14694037
    Search in Google Scholar
  11. [11] Ferner R, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A. Guidelines for the diagnosis and management of individuals with Neurofibromatosis 1. J Med Genet. 2007;44(2):81-88.10.1136/jmg.2006.045906259806317105749
    Search in Google Scholar
  12. [12] Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol. 2002. 17:548-54.10.1177/08830738020170080212403552
    Search in Google Scholar
  13. [13] Friedrich RE, Hartmann M, Mautner VF. Malignant peripheral nerve sheath tumors (MPNST) in NF1-afected children. Anticancer Res. 2007;27:1957-60.
    Search in Google Scholar
  14. [14] Gill DS, Hyman SL, Steinberg A, North KN. Age-related fndings on MRI in Neurofibromatosis type 1. Pediatr Ra-diol. 2006;31:1048-1056.10.1007/s00247-006-0267-2
    Search in Google Scholar
  15. [15] Gutmann, D H, Aylsworth A, Carey JC, Korf B, Marks J, Py-eritz RE, Rubenstein A, Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibroma-tosis 1 and Neurofibromatosis 2. JAMA. 1997;278, 51-57.
    Search in Google Scholar
  16. [16] Hsu TR, Wong TT, Chang FC Ho DM, Tang RB, Thien PF, Chang KP. Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children. Childs Nerv Syst. 2008;24:1457–1461.10.1007/s00381-008-0707-4
    Search in Google Scholar
  17. [17] Hyman SL, Gill DS, Shores EA, Steinberg A, North KN. T2 hyperintensities in children with Neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry. 2007 Oct;78(10):1088-91.10.1136/jnnp.2006.108134
    Search in Google Scholar
  18. [18] Joubilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoetiology of Neurofibromatosis 1, Am J Pathol. 2011; May;178(5):1932-9.10.1016/j.ajpath.2010.12.056
    Search in Google Scholar
  19. [19] Kayes LM, Burke W, Ricardi VM, Bennett R, Ehrlich P, Ru-benstein A, Stephens K. Deletions spanning the neuro-fbromatosis type 1 gene: identifcation of phenotype in fve patients, Am J Hum Genet. 1994;54: 424–436.
    Search in Google Scholar
  20. [20] Kluwe L, Friedrich RE, Peiper M, Friedman J, Mautner VF. Constitutional NF1 mutations in Neurofibromatosis type 1 patients with malignant peripheral nerve sheath tumors. Hum Mutat. 2003;22:420.10.1002/humu.9193
    Search in Google Scholar
  21. [21] Korf BR. Clinical features and pathobiology of neurofibro-matosis 1, J Child Neurol. 2002;17(8):573–577.10.1177/088307380201700806
    Search in Google Scholar
  22. [22] Landau M. and Krafchk BR. The diagnostic value of cafe'-au-lait macules, J Am Acad Dermatol. 1999;40:877-90.10.1016/S0190-9622(99)70075-7
    Search in Google Scholar
  23. [23] Listernick R, Charrow J, Greenwald MJ, Esterly NB. Optic gliomas in children with Neurofibromatosis type 1. J Pe-diatr. 1989;114:788-92.10.1016/S0022-3476(89)80137-4
    Search in Google Scholar
  24. [24] Lopes JR, Munis M P, Soares A, Sanches RA, Goloni-Bertol-lo EM, Pavarino-Bertelli EC, Unidentifed bright objects on brain MRI in children as a diagnostic criterion for neu-rofbromatosis type 1. Pediat Radiol. 2008;38(3):305-310.10.1007/s00247-007-0712-x18231788
    Search in Google Scholar
  25. [25] Lund AM, Skovby F. Optic gliomas in children with neu-rofbromatosis type 1. Eur J of Pediatr. 1991;150: 835-838.10.1007/BF019550021743214
    Search in Google Scholar
  26. [26] Mahoney DH Jr, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW, James HE, Dufner PK, Kun LE. Carboplatin is efective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study, Neuro Oncol. 2000;2:213-220.10.1093/neuonc/2.4.213
    Search in Google Scholar
  27. [27] Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroz L, Clark R, OConnell P, Cawthon RM, Innis MA, McCormik F. The GAP-related domain of the Neurofibromatosis type 1 gene product interacts with ras p21. Cell 63, 1990;843-849.10.1016/0092-8674(90)90150-D
    Search in Google Scholar
  28. [28] McGaughran JM, Harris DI, Donnai D, Teare D, MacLeod R, Westerbeek R, Kingston H, Super M, Harris R, Evans DG. A clinical study of type 1 Neurofibromatosis in north west England. J Med Genet. 1999;36:192-6.
    Search in Google Scholar
  29. [29] 2Messiaen L and Wimmer K. Mutation analysis of the NF1 gene by cDNA-based sequencing of the coding region. In Goncalves Cunha K.S., Geller M. (Eds.) Advances in Neuro-fbromatosis Research, Nova Science, Inc., New York 2012; 89–108, ISBN: 978-1-61324-661-0
    Search in Google Scholar
  30. [30] National Institutes of Health Consensus Development Conference Statement: Neurofibromatosis. Bethesda, Md, USA, 13-15 July 1987. Neurofibromatosis 1988;1:172-8.
    Search in Google Scholar
  31. [31] Nemethova M, Bolcekova A, Ilencikova D, Durovcikova D, Hlinkova K, Hlavata A, Kovacs L, Kadasi L, Zatkova A. Thirty-Nine Novel Neurofibromatosis 1 (NF1) Gene Mutations Identifed in Slovak Patients, Ann Hum Genet. 2013;77(5):364-79.10.1111/ahg.12026
    Search in Google Scholar
  32. [32] North KN, Riccardi V, Samango-Sprouse C, Ferner R, Moore B, Legius E, Ratner N, Denckla MB. Cognitive function and academic performance in Neurofibromatosis 1: Consensus statement from the NF1 cognitive disorders task force. Neurology 1997, 48:1121–1127.10.1212/WNL.48.4.1121
    Search in Google Scholar
  33. [33] Otsuka F, Kawashima T, Imakado S, Usuki Y, Hon-Mura S. Lisch nodules and skin manifestation in Neurofibromato-sis type 1, Arch. Derm. 2001;137:232-233.
    Search in Google Scholar
  34. [34] Parsa CF, Hoyt CS, Lesser RL, Weinstein JM, Strother CM, Muci-Mendoza R, Ramella M, Manor RS, Fletcher WA, Repka MX, Garrity JA, Ebner RN, Monteiro ML, McFadz-ean RM, Rubtsova IV, Hoyt WF. Spontaneous Regression of Optic Gliomas Thirteen Cases Documented by Serial Neuroimaging, Arch Ophthalmol. 2001;119:516–529.
    Search in Google Scholar
  35. [35] Petrák B and Filouš A. Význam vyšetření predního seg-mentu oka pro diagnostiku Neurofibromatosis von Reck-linghausen, Čs. Pediatrie 1998;53,6, 328-331
    Search in Google Scholar
  36. [36] Sharif S, Upadhyaya M, Ferner R, Majounie E, Shenton A, Baser M, Thakker N, Evans DG. Molecular analysis of individuals with Neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and assessment of genotype-phenotype correlations, J Med Genet. 2011;48:256–260.10.1136/jmg.2010.081760
    Search in Google Scholar
  37. [37] Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, Evans DG. Second primary tumors in neurof-bromatosis 1 patients treated for optic gliomas: substantial risks after radiotherapy, J Clin Oncol. 2006;24:2570– 2575.10.1200/JCO.2005.03.8349
    Search in Google Scholar
  38. [38] Singhal S, Birch JM, Kerr B, LAshford L, Evans DG. Neuro-fbromatosis type 1 and sporadic optic gliomas, Arch Dis Child. 2002;87:65–70.10.1136/adc.87.1.65
    Search in Google Scholar
  39. [39] Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzha-nova N, Giovannini S, Evans DG, Howard E, Kerr B, Grifths S, Consoli C, Side L, Adams D, Pierpont M, Hachen R, Bar-nicoat A, Li H, Wallace P, Van Biervliet J P, Stevenson D, Vis-kochil D, Baralle D, Haan E, Riccardi V, Turnpenny P, Lazaro C, Messiaen L. An absence of cutaneous neurofibromas associated with 3-bp inframe deletion in exon 17 of the NF1 gene (c2970-2972 del AAT); evidence of a clinically signifcant NF1 phenotype correlation. Am J Hum Genet. 2007;80: 140–151.10.1086/510781
    Search in Google Scholar
  40. [40] Vraa S, Nielsen OS, Sneppen O, Jurik AG, Jensen OM, Prognostic factors in soft tissue sarcomas: the Aarhus experience, Eur J Cancer. 1998;34(12):1876-82.10.1016/S0959-8049(98)00233-0
    Search in Google Scholar
  41. [41] Yang JC, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA. Randomized prospective study of the beneft of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity, J Clin Oncol. 1998;16(1):197-203.10.1200/JCO.1998.16.1.1979440743
    Search in Google Scholar
  42. [42] Yunoue S, Tokuo H, Fukunaga K, Feng L, Ozawa T, Nishi T, Kikuchi A, Hattori S, Kuratsu J, Saya H, Araki N. Neu-rofbromatosis type I tumor suppressor neurofibromin regulates neuronal diferentiation via its GTPase activating protein function toward Ras. J Biol Chem. 2003;278, 26958–26969.
    Search in Google Scholar
DOI: https://doi.org/10.2478/afpuc-2014-0003 | Journal eISSN: 2453-6725
Journal RSS Feed
Language: English
Submitted on: Feb 20, 2014
|
Accepted on: Apr 20, 2014
|
Published on: Aug 30, 2014
Published by: Comenius University in Bratislava, Faculty of Pharmacy
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Neurofibromatosis,
genetic disorder,
variable clinical manifestation,
diagnostic criteria,
genetic counselling,
malignancy,
follow-up,
broad cooperation with specialists
Related subjects:
Pharmacy,
Pharmacy, other

© 2014 A. Bolčeková, A. Hlavatá, A. Zat'ková, M. Némethová, M. Holobradá, P. Sýkora, A. Gerinec, K. Husáková, D. Ilenčíková, L Kovács, published by Comenius University in Bratislava, Faculty of Pharmacy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 61 (2014): Issue 1 (August 2014)Next article